Program
ZP9830
A development code.
Its studies are mostly in Psoriasis, led by Zealand Pharma.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Zealand Pharma | 22 open or running | phase 1since Nov 7, 2024 | Nov 7, 2024 | Apr 2027phase 1 · NCT07733089 |
Also a collaborator on its studies: ICON Clinical Research.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 7, 2024First study: phase 1 study in Healthy VolunteersFirst studyNCT06682975 · 124 planned · Netherlands
- Jun 15, 2026Phase 1 study in Plaque PsoriasisNCT07733089 · 32 planned · Netherlands
Ahead
- Apr 2027Primary completion: phase 1 study in Plaque PsoriasisNCT07733089
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07733089Plaque Psoriasis · Netherlands | 1 | Recruiting | Apr 2027 | 32 |
| NCT06682975Healthy Volunteers · Netherlands | 1 | Recruiting | Aug 2026 | 124 |
How it is read
Names in the registry
- “ZP9830”, 2 entries
Codes read as this program: ZP9830.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.